Effects of a Botanical Extract on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The Acute Effects of Sideritis Scardica (Greek Mountain Tea) on Cognitive Performance and Cerebral Blood Flow in Healthy Adults
The goal of this clinical trial is to learn how a study product affects cognitive performance and cerebral responses in adults. The study will also collect information about the safety of the study product. Participants will attend a screening visit followed by two study visits. During the study visits, participants will complete computerized cognitive assessments before and after consuming the study product and will wear a NIRS headband to record cerebral responses. Researchers will also monitor participants for adverse events and changes in medications or supplements during the study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
This clinical trial investigates the acute effects of a Sideritis scardica study product on cognitive performance and cerebral responses during cognitive tasks in adults.
Participants will undergo computerized cognitive assessments together with near infrared spectroscopy (NIRS) recording before and after consumption of the study product. Cognitive testing includes choice reaction time (CRT) and rapid visual information processing (RVIP) tasks. NIRS recording is performed during the assessment periods to characterize cerebral responses associated with cognitive task performance.
Following screening, eligible participants will attend two intervention visits. The first intervention visit represents Day 1, and the second is scheduled approximately 8 days later. At each visit, cognitive and NIRS assessments are performed before study product consumption and are repeated after consumption. Standardized resting NIRS recording periods are incorporated into the assessment sequence.
Adverse events and relevant changes in medical conditions, medications, and supplements will be monitored throughout the study.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Cynthia G. Suarez, PhD.
- Phone Number: +4916098144462
- Email: cynthia.suarez-rizzo@martin-bauer.com
Study Locations
-
-
RLP
-
Andernach, RLP, Germany, 56626
- Finzelberg
-
-
-
-
-
Cork, Ireland
- Atlantia Clinical Trials
-
Contact:
- Scientific Director
- Phone Number: 7442 +353 (0) 021-430
- Email: krea@atlantiatrials.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be able to give written informed consent.
- Be between 18-70 years of age.
- BMI between 18.5 and 30.0 kg/m2
- Willing to refrain from consuming alcohol for 24 h, non-habitual stimulants for 18 h prior to Visit 2 (Day 1) and Visit 3 (Day 8).
- Willing and able to comply with all study procedures and consume the study product as instructed at each study visit.
Exclusion Criteria:
-
Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding.
-
Participants currently of biological childbearing potential but not using a continuous effective method of contraception as determined by the investigator.
-
Has a history of drug and/or alcohol abuse (within 12 months prior to visit 1)
-
Participants that are habitual smokers or vapers
-
High caffeine intake, >400mg/day (approximately equivalent to ≥4 cups of coffee per day
-
Has food allergies, or other issues with foods, that would preclude intake of the study products.
-
Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history. Excluded health conditions include:
- Uncontrolled hypertension
- Clinically significant neurological or mental health conditions (history of stroke/TIA, epilepsy, traumatic brain injury with loss of consciousness, diagnosed ADHD, major depressive disorder within last 6 months)
- Diagnosed cognitive impairment
- Type I or II diabetes
- Clinically significant cardiovascular, liver and renal disease
- Diagnosed gastrointestinal conditions (IBD, coeliac disease)
-
Currently or recently taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. Prohibited medications include:
a) Prescription medications such a hypnotic, BDZs, antidepressants, antipsychotics, stimulants, beta-blockers, vasodilators, nootropics, and any psychoactive drugs (in the past 2 weeks prior to visit 1)
-
Current or recent (in the past 2 weeks) use of prohibited nutritional and non-nutritional supplements, that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator, including:
- Ginseng, ginkgo biloba, Luteolin, Apigenin supplements
- Products containing Sideritis, Sage, Thymus and Oregano
-
Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
-
Participants may not be participating in other clinical studies. If the participant has previously taken part in an experimental study, the Investigator must ensure sufficient time has elapsed before entry to this study to ensure the integrity of the results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Placebo supplement containing carrier material only |
Placebo supplement containing carrier material only |
|
Experimental: Siderits
Sideritis supplement administered at an estimated daily dose |
Sideritis scardica preparation (Greek Mountain Tea) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference between the Sideritis scardica (Greek Mountain Tea) extract, and placebo in the change from pre-dose assessment to the post-dose assessment period in Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1)
Time Frame: Baseline, day 1, day 7
|
Evaluate the acute effects of Greek Mountain Tea extract, compared with placebo on Cognitive performance (Choice Reaction Time Task x 5 and RVIP x 1) |
Baseline, day 1, day 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive performance during the test called Choice Reaction Time (CRT)
Time Frame: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of Choice Reaction Time (CRT) with the measurement of following parameters: Choice Reaction Time accuracy, Choice Reaction Time (overall reaction time), Choice Reaction Time (correct response reaction time), Choice Reaction Time Number of Errors (%) |
Baseline, day 1, day 7
|
|
Cognitive Performance: Rapid Visual Information Processing (RVIP)
Time Frame: Baseline, day 1, day 7
|
Difference between Sideritis scardica (Greek Mountain Tea) extract and placebo in the change from pre-dose assessment in cognitive performance outcomes of RVIP response time, RVIP false alarms, RVIP Number of Correct Detections (Hits) |
Baseline, day 1, day 7
|
|
Cerebral total haemoglobin approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation as assessed by near-infrared spectroscopy (NIRS) analysis to determine total haemoglobin. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenation
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis, concurrent changes in tissue saturation index to determine total oxygen saturation. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral oxygenated haemoglobin (HbO2) approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determine oxygenated haemoglobin (HbO2) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
|
Cerebral deoxygenated hemoglobin (HHb) approximately 150 to 240 minutes after administration
Time Frame: Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Cerebral oxygenation assessed by near-infrared spectroscopy (NIRS) analysis to determinedeoxygenated hemoglobin (HHb) levels. |
Baseline, day 1, day 7, approximately 150 to 240 minutes after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Heiner F, Feistel B, Wink M. Sideritis scardica extracts inhibit aggregation and toxicity of amyloid-beta in Caenorhabditis elegans used as a model for Alzheimer's disease. PeerJ. 2018 Apr 30;6:e4683. doi: 10.7717/peerj.4683. eCollection 2018.
- Wightman EL, Jackson PA, Khan J, Forster J, Heiner F, Feistel B, Suarez CG, Pischel I, Kennedy DO. The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis scardica (Greek Mountain Tea) Extract: A Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans. Nutrients. 2018 Jul 24;10(8):955. doi: 10.3390/nu10080955.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FB_AF216
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The IPD dataset will include de-identified participant-level demographic and baseline characteristics, treatment allocation, and individual results for the primary and secondary outcome measures included in the published analyses. Derived variables necessary to reproduce the reported statistical analyses may also be included. Direct identifiers and other information that could reasonably permit participant identification will not be shared.
IPD Sharing Time Frame
Start date: Following completion of the study and publication of the primary study results.
End date: Available thereafter upon reasonable request, subject to applicable data-retention requirements and sponsor policies.
IPD Sharing Access Criteria
Qualified researchers may request access to de-identified IPD underlying the reported results and relevant supporting documents. Requests must include a scientifically sound proposal and will be reviewed by the study sponsor/data custodian. Approved applicants will receive only the data necessary for the approved purpose through an appropriate secure data-sharing mechanism and, where applicable, under a data-use agreement. No directly identifiable participant information will be shared.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.